Total Payments
$17,609
2024 Payments
$2,626
Companies
73
Transactions
660
Medicare Patients
800
Medicare Billing
$74,344
Payment Breakdown by Category
Food & Beverage$14,559 (82.7%)
Consulting$1,688 (9.6%)
Travel$700.57 (4.0%)
Education$661.32 (3.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $14,559 | 643 | 82.7% |
| Consulting Fee | $1,688 | 1 | 9.6% |
| Travel and Lodging | $700.57 | 6 | 4.0% |
| Education | $661.32 | 10 | 3.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Cardinal Health 414, LLC | $2,546 | 10 | $0 (2017) |
| Janssen Biotech, Inc. | $1,021 | 31 | $0 (2024) |
| PFIZER INC. | $962.53 | 46 | $0 (2024) |
| Merck Sharp & Dohme LLC | $950.85 | 48 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $904.71 | 39 | $0 (2024) |
| Genentech USA, Inc. | $782.26 | 39 | $0 (2024) |
| Amgen Inc. | $781.43 | 39 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $774.77 | 40 | $0 (2024) |
| Celgene Corporation | $748.31 | 24 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $606.06 | 33 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,626 | 113 | PFIZER INC. ($399.37) |
| 2023 | $3,125 | 139 | Janssen Biotech, Inc. ($327.57) |
| 2022 | $2,893 | 123 | Astellas Pharma US Inc ($315.15) |
| 2021 | $1,974 | 79 | Celgene Corporation ($260.83) |
| 2020 | $2,301 | 104 | Amgen Inc. ($345.24) |
| 2019 | $1,756 | 87 | Merck Sharp & Dohme Corporation ($163.48) |
| 2018 | $153.07 | 3 | Celgene Corporation ($115.46) |
| 2017 | $2,780 | 12 | Cardinal Health 414, LLC ($2,546) |
All Payment Transactions
660 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Tolmar, Inc. | ELIGARD (Drug) | Food and Beverage | Cash or cash equivalent | $20.02 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $25.68 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $1.18 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $110.35 | General |
| Category: NONE | ||||||
| 11/13/2024 | Agios Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $26.53 | General |
| 08/30/2024 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $26.82 | General |
| Category: Monoclonal Antibody | ||||||
| 08/28/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $21.48 | General |
| Category: ONCOLOGY | ||||||
| 08/28/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $19.54 | General |
| 08/28/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $12.32 | General |
| Category: Oncology | ||||||
| 08/26/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $22.08 | General |
| Category: Oncology | ||||||
| 08/21/2024 | RECORDATI_RARE_DISEASES_INC. | SYLVANT (Drug) | Food and Beverage | In-kind items and services | $16.32 | General |
| Category: ONCOLOGIC AGENT | ||||||
| 08/19/2024 | SERVIER PHARMACEUTICALS LLC | IDHIFA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Oncology | ||||||
| 08/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $25.11 | General |
| Category: Oncology | ||||||
| 08/12/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $26.14 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 08/09/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $24.85 | General |
| Category: Oncology | ||||||
| 08/08/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $16.42 | General |
| Category: Oncology | ||||||
| 08/06/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $23.21 | General |
| Category: ONCOLOGY | ||||||
| 08/05/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $27.73 | General |
| Category: Hematology/Oncology | ||||||
| 08/03/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $13.08 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $17.72 | General |
| Category: ONCOLOGY | ||||||
| 07/31/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $26.31 | General |
| Category: ONCOLOGY | ||||||
| 07/30/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $27.61 | General |
| Category: Oncology | ||||||
| 07/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $27.54 | General |
| Category: ONCOLOGY | ||||||
| 07/24/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 07/23/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $16.44 | General |
| Category: Hematology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 124 | 414 | $32,965 | $10,318 |
| 2022 | 8 | 210 | 670 | $81,096 | $20,686 |
| 2021 | 9 | 247 | 745 | $88,607 | $21,339 |
| 2020 | 8 | 219 | 548 | $84,305 | $22,001 |
Total Patients
800
Total Services
2,377
Medicare Billing
$74,344
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 30 | 62 | $20,203 | $6,111 | 30.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 16 | 26 | $5,752 | $1,790 | 31.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 39 | 153 | $1,800 | $1,252 | 69.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 39 | 173 | $5,210 | $1,165 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 36 | 99 | $33,121 | $9,544 | 28.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 13 | 30 | $14,298 | $3,345 | 23.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 12 | 21 | $9,458 | $2,574 | 27.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 20 | 31 | $7,010 | $2,100 | 30.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 53 | 195 | $6,609 | $1,286 | 19.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 11 | 33 | $3,517 | $806.67 | 22.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 53 | 190 | $1,765 | $543.38 | 30.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 12 | 71 | $5,318 | $487.34 | 9.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 33 | 66 | $22,081 | $6,527 | 29.6% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 17 | 58 | $27,643 | $5,646 | 20.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 16 | 28 | $12,611 | $3,571 | 28.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 19 | 27 | $6,105 | $1,945 | 31.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 62 | 203 | $6,880 | $1,393 | 20.3% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2021 | 16 | 61 | $6,501 | $1,154 | 17.8% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 14 | 64 | $4,794 | $556.40 | 11.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 58 | 195 | $1,812 | $525.75 | 29.0% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2021 | 12 | 43 | $180.17 | $20.77 | 11.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 24 | 71 | $23,754 | $6,153 | 25.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 33 | 48 | $15,643 | $4,359 | 27.9% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 13 | 36 | $17,158 | $4,295 | 25.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 29 | 47 | $10,646 | $2,972 | 27.9% |
About Dr. Ashok Kumar, MD
Dr. Ashok Kumar, MD is a Medical Oncology healthcare provider based in Boca Raton, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/11/2005. The National Provider Identifier (NPI) number assigned to this provider is 1225030141.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ashok Kumar, MD has received a total of $17,609 in payments from pharmaceutical and medical device companies, with $2,626 received in 2024. These payments were reported across 660 transactions from 73 companies. The most common payment nature is "Food and Beverage" ($14,559).
As a Medicare-enrolled provider, Kumar has provided services to 800 Medicare beneficiaries, totaling 2,377 services with total Medicare billing of $74,344. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Boca Raton, FL
- Active Since 08/11/2005
- Last Updated 09/27/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1225030141
Products in Payments
- KEYTRUDA (Biological) $905.71
- OPDIVO (Biological) $452.40
- DARZALEX (Biological) $425.01
- Revlimid (Drug) $395.32
- JAKAFI (Drug) $380.25
- Tavalisse (Drug) $328.91
- LIBTAYO (Biological) $314.59
- ERLEADA (Drug) $255.98
- TAGRISSO (Drug) $248.94
- LYNPARZA (Drug) $224.19
- INLYTA (Drug) $218.01
- Kyprolis (Drug) $206.28
- SARCLISA (Biological) $196.69
- BOSULIF (Drug) $190.75
- KISQALI (Drug) $181.30
- VERZENIO (Drug) $179.15
- ADCETRIS (Biological) $176.91
- IBRANCE (Drug) $169.79
- TUKYSA (Drug) $167.00
- Lenvima (Drug) $165.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.